Technical Analysis for PAR - Paradigm Biopharmaceuticals Ltd
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -5.00% | |
| NR7 | Range Contraction | -5.00% | |
| Narrow Range Bar | Range Contraction | -5.00% | |
| Inside Day | Range Contraction | -5.00% | |
| Wide Bands | Range Expansion | -5.00% | |
| Oversold Stochastic | Weakness | -5.00% | |
| Wide Bands | Range Expansion | -5.00% | |
| Gapped Up | Strength | -5.00% |
| Alert | Time |
|---|---|
| 10 DMA Resistance | about 12 hours ago |
| 10 DMA Support | about 14 hours ago |
| Non-ADX 1,2,3,4 Bearish Retracement Entry | about 14 hours ago |
| Fell Below Previous Day's Low | about 14 hours ago |
| Down 3% | about 14 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
Paradigm Biopharmaceuticals Limited is a biopharmaceutical company focused on repurposing the drug pentosan polysulfate sodium (PPS) for the treatment of inflammation. The Company is engaged in researching and developing therapeutic products for human use. The Company is a drug repurposing company, which seeks to find new uses for old drugs. The Company has commenced the open labelled Phase II clinical trial, investigating the role of the drug PPS in treating traumatic Bone Marrow Lesions. The Company's Rhinosul has properties consisting of both histamine stabilizing and anti-inflammatory properties. The Company focuses on repurposing PPS under ZILOSUL name, as a treatment for bone marrow edema (BME) lesions following traumatic injury.
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Drugs Pharmaceuticals Clinical Trial Biopharmaceutical Medical Specialties Pharmaceutical Industry Therapeutic Product Therapeutic Products Medication Organ Systems Inflammation Osteochondritis Dissecans
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Drugs Pharmaceuticals Clinical Trial Biopharmaceutical Medical Specialties Pharmaceutical Industry Therapeutic Product Therapeutic Products Medication Organ Systems Inflammation Osteochondritis Dissecans
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.165 |
| 52 Week Low | 0.265 |
| Average Volume | 592,999 |
| 200-Day Moving Average | 0.537 |
| 50-Day Moving Average | 0.349 |
| 20-Day Moving Average | 0.321 |
| 10-Day Moving Average | 0.294 |
| Average True Range | 0.023 |
| RSI (14) | 35.06 |
| ADX | 24.12 |
| +DI | 12.392 |
| -DI | 26.261 |
| Chandelier Exit (Long, 3 ATRs) | 0.315 |
| Chandelier Exit (Short, 3 ATRs) | 0.335 |
| Upper Bollinger Bands | 0.379 |
| Lower Bollinger Band | 0.263 |
| Percent B (%b) | 0.19 |
| BandWidth | 36.199 |
| MACD Line | -0.021 |
| MACD Signal Line | -0.018 |
| MACD Histogram | -0.0027 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 0.315 | ||||
| Resistance 3 (R3) | 0.317 | 0.308 | 0.310 | ||
| Resistance 2 (R2) | 0.308 | 0.301 | 0.308 | 0.308 | |
| Resistance 1 (R1) | 0.297 | 0.296 | 0.293 | 0.295 | 0.307 |
| Pivot Point | 0.288 | 0.288 | 0.286 | 0.288 | 0.288 |
| Support 1 (S1) | 0.277 | 0.281 | 0.273 | 0.275 | 0.263 |
| Support 2 (S2) | 0.268 | 0.276 | 0.268 | 0.262 | |
| Support 3 (S3) | 0.257 | 0.268 | 0.260 | ||
| Support 4 (S4) | 0.255 |
